v160
Vaccineexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 25, 2013 (NCT01986010)
Timeline
Indications
Studied for
Mechanism of action
- CytomegalovirusImmunity, active
Cytomegalovirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- v160
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03840174 | Phase 1 | Mar 8, 2019 | Merck |
| NCT03486834 | Phase 2 | Apr 30, 2018 | Merck |
| NCT01986010 | Phase 1 | Nov 25, 2013 | Merck |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 3 | 3 | 2 | 2013 |
1 organizations
Page 1 / 1